SubscribeSign In
LeaderPortfolio
Billionaire Profile
Hu Kaijun
Global Rank
#1103

Image: Unsplash Contributor | Unsplash License | via Unsplash

Hu Kaijun

CEO, Pharmaceuticals
CHINA
Real-Time Net Worth
$3.923B
Estimated based on Pharmaceuticals stock value as of April 20, 2026
-1.58% (24h)
Age
64
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
CHINA

Biography

Hu Kaijun, a prominent figure in China's pharmaceutical industry, is the chairman and CEO of China Grand Enterprises, an investment firm with interests spanning healthcare, real estate, agriculture, and financial services. As of March 25, 2026, his estimated net worth is $3.9 billion. Hu Kaijun's primary wealth source is his stake in Grand Pharmaceutical and Huadong Medicine. His career includes leading China Grand Enterprises, which owns three publicly traded companies: Grand Pharmaceutical, Huadong Medicine, and Grand Industrial Holding. Hu's leadership has driven strategic acquisitions, including the purchase of BlackSwan Vascular in the U.S. in 2023.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/20/2026

Wealth Over Time

In-Depth Profile

Early Life and Career

Information regarding Hu Kaijun's early life and educational background is limited in publicly available sources. However, it is known that he is 64 years old as of March 25, 2026. He is the chairman and CEO of China Grand Enterprises, an investment company.

Rise to Success

Hu Kaijun's success is closely tied to his strategic leadership and investment acumen within China Grand Enterprises. The company has diversified interests, with a primary focus on the healthcare sector. China Grand is the parent company of Grand Pharmaceutical, Huadong Medicine, and Grand Industrial Holding. The acquisition of BlackSwan Vascular for $37.5 million in 2023 was a key move in expanding the company's global footprint.

Key Business Strategies

Hu Kaijun's business strategies include strategic investments and acquisitions, particularly in the healthcare sector. His leadership has seen Grand Pharmaceutical expanding its presence in the international market, acquiring and collaborating with companies to enhance its portfolio. This approach has led to the transfer of medical technologies from European and U.S. startups to China.

Philanthropy

Details about Hu Kaijun's philanthropic activities and the exact amounts are not readily available in the search results.

Career Milestones

2000

Huadong Medicine went public

Hu Kaijun is the chairman of Huadong Medicine

2018

Acquired a stake in Sirtex Medical

A listed arm of China Grand Enterprises acquired a 49% stake in Australia's medical device maker Sirtex

2023

Acquired BlackSwan Vascular

Grand Pharmaceutical agreed to buy 87.5% of U.S.-based vascular drug maker BlackSwan Vascular

Philanthropy & Social Impact

Not Available

Not Available

$XB

Not Available

Business Philosophy & Leadership

Notable Quotes

"Not Available"

Leadership Principles

Strategic Investment

Focusing on strategic acquisitions and collaborations to expand market presence.

Global Expansion

Expanding the company's global footprint through acquisitions

Controversies & Challenges

2013

Transformation of SOE

Questions raised about the transformation of a state-owned enterprise into China Grand Enterprises through transactions that raised questions about corporate governance and asset valuation

Compare Hu Kaijun

Net Worth Face-off
Hu Kaijun vs Elon Musk
Compare Wealth →
Net Worth Face-off
Hu Kaijun vs Jeff Bezos
Compare Wealth →
Net Worth Face-off
Hu Kaijun vs Mark Zuckerberg
Compare Wealth →